Ridaforolimus (AP23573)
Published: Oct 15, 2008 8:00 am
| Brand Name: | |
| Generic Name: | ridaforolimus (formerly deforolimus) |
| Code Name: | AP23573 |
| Company: | Ariad Pharmaceuticals & Merck |
| FDA Clinical Phase: | 1 |
Description:
Ridaforolimus, formerly known as deforolimus, is a drug used to treat soft tissue and bone sarcomas. It is also being studied in the treatment of other solid tumors and hematologic cancer. Ridaforolimus may control the growth of blood vessels to the cancer. It belongs to the family of drugs called rapamycin analogs.
Clinical Trials:
For a list of clinical trials studying BI-505 for the treatment of multiple myeloma, see ClinicalTrials.gov.
Official website for Ridaforolimus: http://www.ariad.com/wt/tertiarypage/ridaforolimus
Source: Wikipedia, ridaforolimus, http://en.wikipedia.org/wiki/Ridaforolimus (as of November 14, 2009)
Related Articles:
- FDA Approves Once-Weekly Dosing And Revised Safety Information For Kyprolis
- Nelfinavir Shows Only Limited Success In Overcoming Revlimid Resistance In Multiple Myeloma Patients
- Latest Myeloma Research To Be Presented At The American Society Of Clinical Oncology Annual Meeting (ASCO 2018)
- Getting To Know: TNB-383B
- Two Darzalex Clinical Trials Halted; Little Impact Expected On Drug’s Use In Multiple Myeloma
